Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 6.39 USD 6.15%
Market Cap: 943m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Operating Margin
Adaptive Biotechnologies Corp

-94.3%
Current
-120%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-94.3%
=
Operating Profit
-167.1m
/
Revenue
177.3m

Operating Margin Across Competitors

Country US
Market Cap 942.9m USD
Operating Margin
-94%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202.3B USD
Operating Margin
17%
Country US
Market Cap 166.6B USD
Operating Margin
21%
Country KR
Market Cap 66.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.8B USD
Operating Margin
24%
Country US
Market Cap 36.3B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 162B CNY
Operating Margin
27%
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
942.9m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.94 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-94.3%
=
Operating Profit
-167.1m
/
Revenue
177.3m
What is the Operating Margin of Adaptive Biotechnologies Corp?

Based on Adaptive Biotechnologies Corp's most recent financial statements, the company has Operating Margin of -94.3%.